Accendra Health Inc/va/ (ACH) · Nov 5, 2026 · Earnings

Accendra Health earnings miss as EBITDA outlook slashed in turnaround reset

Miss — Adj. EPS -$0.23 vs ~$0.01 consensus; FY EBITDA could fall to ~$217M from $310M midpoint

Accendra Health’s third-quarter earnings missed published expectations, with revenue falling and adjusted EBITDA guidance cut sharply as its new CEO launches a turnaround.

Accendra Health is now a narrower, pure-play patient-direct home-care business built around Apria and Byram after the Products & Healthcare Services sale, but the post-separation model has not stabilized. Its prior 2026 plan called for $2.45–$2.55 billion of revenue and $300–$320 million of adjusted EBITDA, so the market was already expecting a difficult transition.

The quarter missed on both sales and profitability. Revenue was $601.8 million versus a published consensus of roughly $618 million, while adjusted EPS was a $0.23 loss against a roughly $0.01 consensus loss. The operating deterioration is visible against last year: adjusted EBITDA fell to $47.8 million from $92.2 million, and adjusted earnings moved from $19.9 million of income to an $18.0 million loss. 〔0〕

MetricQ3 2026Q3 2025Consensus / prior guide
Net revenue (Third Quarter Results)$601.8M (-13.7%)$697.3M~$618M consensus
Adj. EPS (Third Quarter Results)-$0.23$0.25~$0.01 consensus
Adj. EBITDA (Third Quarter Results)$47.8M (-48.1%)$92.2M—
Free cash flow (Third Quarter Results)$5.8M (-80.0%)$29.2M—
FY adjusted EBITDA outlook (Financial Outlook)Could be ~$217M—$310M midpoint
Cash (Balance Sheet)$26.6M——
Net debt (Debt reconciliation)$1.728B——

The guidance cut is the more important news. Management now expects revenue only at the bottom of its existing range and says adjusted EBITDA could be as much as 30% below the prior $310 million midpoint—an implied floor near $217 million. That is not a routine reset; it says the earnings damage is broader than one quarter and that the prior recovery path is no longer credible.

The new CEO has acknowledged a business problem, not just temporary noise. Kenny Gardner-Smith said 2026 results had “fallen well short” of expectations and introduced a value-creation plan, but the filing provides no quantified savings, timing, or operating targets. That leaves the turnaround as an intention rather than evidence of improved execution. 〔1〕

Cash generation and balance-sheet flexibility remain weak. Nine-month free cash flow was negative $21.3 million and operating cash flow was negative $93.5 million, while cash fell to $26.6 million against $1.728 billion of net debt. The quarter did produce positive free cash flow, but the year-to-date figures show that the company is still consuming cash while funding a heavily levered turnaround.

Bottom line: This is a clear earnings miss followed by a substantial outlook reduction, not merely a noisy post-sale comparison. The filing weakens the current turnaround story until management can show that the new plan reverses the earnings and cash-flow deterioration.‌

What to watch next

Value creation plan details, expected over the coming months

Original filing on SEC EDGAR

More Accendra Health Inc/va/ news

Accendra Health earnings miss as EBITDA outlook slashed in turnaround reset | ACH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.